psoriasis

AbbVie’s Skyrizi hits the spot in refractory psoriasis
Pharmaphorum
Mon, 03/20/23 - 11:21 am
AbbVie
Skyrizi
psoriasis
Takeda focuses on ‘diverse’ pipeline prospects on heels of two acquisitions
Endpoints
Mon, 02/6/23 - 10:55 am
Takeda
Nimbus Therapeutics
Hutchmed
colorectal cancer
psoriasis
fruquintinib
UCB's bimekizumab finally back on the FDA's review list after May rejection
Fierce Pharma
Wed, 12/28/22 - 08:40 pm
UCB Pharma
psoriasis
bimekizumab
FDA
Dr. Reddy's subsidiary hits the pause button on drug development for psoriasis
Endpoints
Fri, 12/16/22 - 10:32 am
Dr Reddy's
psoriasis
Aurigene
clinical trials
AUR101
Nimbus hopes to best Bristol’s Sotyktu
EP Vantage
Fri, 11/4/22 - 10:15 am
Bristol Myers Squibb
Sotyktu
Nimbus
NDI-034858
psoriasis
The other shoe drops for Immunic
EP Vantage
Fri, 10/21/22 - 10:19 am
Immunic
IMU-935
psoriasis
A biologic’s efficacy in a pill: Dice posts first human data for oral psoriasis med
MedCity News
Tue, 10/11/22 - 03:59 pm
DiCE Therapeutics
biologics
psoriasis
DC-806
Nimbus raises $125M to advance rival to Bristol Myers’ new psoriasis drug
BioPharma Dive
Mon, 09/12/22 - 11:39 pm
Nimbus Therapeutics
psoriasis
Bristol Myers Squibb
Sotyktu
Bristol Myers gets FDA approval for new type of psoriasis drug
BioPharma Dive
Sun, 09/11/22 - 11:09 pm
Bristol Myers Squibb
Sotyktu
FDA
psoriasis
Ventyx touts early data for potential rival to Bristol Myers psoriasis drug
BioPharma Dive
Tue, 08/16/22 - 12:22 pm
Ventyx Biosciences
clinical trials
Bristol Myers Squibb
psoriasis
VTX958
deucravacitinib
Pursuing AbbVie and J&J, Innovent hits primary endpoint in phase 2 psoriasis trial
Fierce Biotech
Wed, 08/10/22 - 10:49 am
Innovent
AbbVie
JNJ
monoclonal antibodies
psoriasis
clinical trials
Plaque psoriasis and psoriatic arthritis: trials to watch in 2022
Clinical Trials Arena
Tue, 08/9/22 - 06:32 am
clinical trials
psoriasis
psoriatic arthritis
Lipidor
AKP-02
Amgen
ABP-654
Hengyi
HPP-737
Galapagos
Jyseleca
FDA Action Alert: Incyte, Arcutis Await Decisions in Vitiligo, Psoriasis
BioSpace
Mon, 07/18/22 - 10:22 am
FDA
Incyte
Arcutis Biotherapeutics
Opzelura
vitiligo
roflumilast
psoriasis
Bristol Myers Squibb, with new positive lupus data in hand, readies TYK2 inhibitor for final test
Fierce Biotech
Wed, 06/1/22 - 09:48 am
Bristol Myers Squibb
lupus
psoriasis
deucravacitinib
FDA approves Roivant drug, the first novel topical plaque psoriasis med in 25 years
MedCity News
Tue, 05/24/22 - 04:40 pm
Roivant
Vtama
FDA
psoriasis
plaque psoriasis
J&J's crown jewel Stelara faces another potential rival as biosim player Alvotech touts trial win
Fierce Pharma
Tue, 05/24/22 - 04:31 pm
Alvotech
Teva Pharmaceutical
JNJ
Stelara
AVT04
biosimilars
psoriasis
UCB’s FDA setback delays competition in U.S. with blockbuster J&J psoriasis drug
MedCity News
Sun, 05/15/22 - 11:12 pm
UCB Pharma
bimekizumab
psoriasis
FDA
JNJ
Bristol Myers on track for 3rd new drug launch of 2022 with latest deucravacitinib data
Fierce Biotech
Thu, 05/12/22 - 10:48 am
Bristol Myers Squibb
deucravacitinib
clinical trials
psoriasis
Amgen
Otezla
Psoriasis and psoriatic arthritis drugs crisscross categories, but derm and rheum docs split on preferences
Endpoints
Mon, 05/9/22 - 11:35 pm
psoriasis
psoriatic arthritis
dermatologists
rheumatologists
FDA knocks Bausch for misleading promotion of psoriasis drug on Lifetime show
RAPS.org
Tue, 04/12/22 - 08:42 pm
Bausch Health
FDA
OPDP
psoriasis
Doubrii

Pages